Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Panel to Discuss Shortening of COVID Booster Interval
A Japanese health ministry advisory panel will discuss the shortening of the current dosing interval for COVID-19 booster shots with both Pfizer and Moderna vaccines at its meeting on October 19. How much it will be shortened is subject to…
To read the full story
Related Article
- COVID Booster Interval to Be Shortened to “At Least 3 Months”
October 20, 2022
- Comirnaty Bags Special Approval in Japan for Kids Aged 6 Months to 4 Years
October 6, 2022
- Pfizer’s BA.4/5-Adapted Comirnaty Grabs Special Approval in Japan
October 6, 2022
- Moderna Files BA.4/5-Tailored COVID-19 Vaccine in Japan
October 5, 2022
- Japan Panel to Discuss Comirnaty for Kids Aged 6 Months to 4 Years on Oct. 5
September 29, 2022
- Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine
September 13, 2022
- Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
- Moderna to File BA.4/5-Targeting Booster Jab in Japan
September 6, 2022
- Pfizer Discussing Filing of BA.5-Based Vaccine with Japanese Authorities
September 1, 2022
- Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
REGULATORY
- Japan Set to Compile Support Measures to Secure MCMs by Year-End
October 15, 2026
- Japan to Weigh Necessary Measures for FY2027 Revision: PM
October 15, 2026
- Japan Eyes Multi-Year Funding to Secure MCMs: Takaichi
October 14, 2026
- Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
- AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
October 13, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…